The Hindu Business Line : Ranbaxy to market Zonisamide

Ranbaxy Laboratories Ltd said that it has entered into a strategic partnership with the US-based Invagen Pharmaceuticals Inc for marketing Zonisamide Capsules, which are used for the treatment of epilepsy, in the US market. Under the agreement, products would be developed and submitted for approval to the USFDA. Ranbaxy Pharmaceuticals Inc (RPI) would market the products under the company's label. Zonisamide Capsules, which are indicated as adjunctive therapy in the treatment of partial seizures in adults with epilepsy, have total annualised sales of $170.30 million, a Ranbaxy statement said. "Such partnerships with companies like Invagen, who have capabilities and competencies to develop bio-equivalent generic product for the marketplace, are naturally beneficial to both organisations while having a positive economic impact on the US healthcare system," the Ranbaxy Inc President, Mr Atul Malhotra, said.

RPI is a wholly owned subsidiary of Ranbaxy Laboratories Ltd. RPI is engaged in the sale and distribution of generic and branded prescription products in the American healthcare system.

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Nava Bharat allots 32-lakh warrants

Reliance Info seeks Rs 85 cr from BSNL

Cummins to source more from India

Orient Paper Mills bags eco award

Lanco firms up Rs 15,000-cr capex for power

GM likely to set up new plant in Maharashtra

LG Electronics launches optical disk drive operations

Nuance Group, Shoppers' Stop to enter airport retail market

Orissa PSUs' jt venture to set up thermal plant

Ranbaxy to market Zonisamide

Hansel Textil enters jt venture with Sewing

Deloitte employees take to voluntary work

Negotiations on between MRPL, Cairn for crude from Rajasthan

Kinetic pins hopes on components biz

Mid Valley plans to invest Rs 300 cr in movies, multiplexes

Kalmar to expand in India

Talukdar, new OIL Director